Clinical Trial Update: A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase I/II study of paclitaxel, carboplatin, and YM155 (survivin suppressor) in patients with solid tumors and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Paclitaxel (Taxol) (paclitaxel)
• YM155 (Survivin suppressor) (YM155)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: NSCLC, Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-04-04